PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/57

A1

(11) International Publication Number: WO 00/07620

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/IB99/01483

(22) International Filing Date: 5 August 1999 (05.08.99)

(30) Priority Data:
PP 5087 5 August 1998 (05.08.98) AU

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US PP 5087 (CIP)
Filed on 5 August 1998 (05.08.98)

(71) Applicant *(for all designated States except US)*: BIOTECH AUSTRALIA PTY. LTD. [AU/AU]; 29 Barcoo Street, P.O. Box 20, Roseville, NSW 2069 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BUNN, Clive, Leighton [AU/AU]; 11 Orchard Street, West Ryde, NSW 2114 (AU). SHARP, Phillip, John [AU/AU]; 26 Darghan Street, Glebe, NSW 2037 (AU).

(74) Agent: STEARNE, Peter, A.; Davies Collison Cave, Level 10, 10 Barrack Street, Sydney, NSW (AU).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROTEASE INHIBITORS FOR USE IN THE TREATMENT OF PSORIASIS

(57) Abstract

Psoriasis may be treated by topical administration of a urokinase inhibitor, such as PAI–2, or a combination of protease inhibitors, such as PAI–2 with other serine protease inhibitors and/or with protease inhibitors such as inhibitors of metalloproteinases, acid proteases, and thiol proteases.